Quince Therapeutics, Inc. (QNCX)
Quince Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in South San Francisco, CA, US. The stock last traded at $32.73, up 6.79% on the session, giving a market capitalisation of $9.1M. On trailing twelve-month figures it carries a trailing P/E of -0.26, a net margin of 0.0%. Its beta of 1.40 implies it has historically moved more than the broad market.
Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations. The company, previously known as Cortexyme, Inc., officially rebranded as Quince Therapeutics, Inc. in August 2022. Established in 2012, Quince Therapeutics is headquartered in South San Francisco, California.
Quince Therapeutics, Inc. is most often compared with the following Healthcare names: